CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER The implant allows for continuous delivery of a GLP-1 receptor agonist, improving cardio-metabolic health and potentially "enhancing quality of life" while extending it, according to the release
Blue Cross began covering Saxenda in 2015 when federal regulators approved it to treat weight loss, adding coverage of Wegovy in 2021 and Zepbound in 2023
If evaluation reveals a suspicious nodule requiring further workup, most endocrinologists will recommend completing the thyroid evaluation before initiating tirzepatide, not because tirzepatide would worsen the nodule, but because establishing a baseline before starting any new medication is sound medical practice
2000 May;71(5):1194-200
New yellowing of the skin or eyes, dark urine, or severe right upper abdominal pain also needs prompt review
The importance of nutrition while taking Mounjaro Sustainable weight loss requires more than just medication